Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 28, 2012

Primary Completion Date

January 23, 2019

Study Completion Date

January 23, 2019

Conditions
Leukemia Lymphocytic Chronic B-Cell
Interventions
DRUG

CC-292

CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.

DRUG

Lenalidomide

Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.

Trial Locations (11)

1090

Allgemeines Krankenhaus Wien, Vienna

1100

Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie, Vienna

4021

AKh Linz, Linz

5020

Universitatsklinik der PMU, Salzburg

10029

Mount Sinai School of Medicine, New York

35805

Clearview Cancer Institute Oncology Specialties, P.C, Huntsville

38120

The West Clinic, Memphis

47905

Horizon Oncology Center, Lafayette

77030

MD Anderson Cancer Center, Houston

07601

Hackensack University Medical Center, Hackensack

Unknown

Universitatsklinik fur Innere Medizin, Innsbruck

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01732861 - Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter